In the primary analysis, NG2-73 had a statistically significant effect on sedation compared with placebo, and as measured by the Observer and the Subject VAS, there was a dose-response relationship. Similar effects were seen with the EBFB, DSST, PVT and posturography. Zolpidem 10 mg had effects that appeared similar to a dose between 3 mg and 5 mg of NG2-73. The duration of action of NG2-73 in the VAS ranged from approximately 1.5 hours for the 1 mg dose to approximately 6 hours with the 10mg dose. Zolpidem had a duration of action of approximately 6 hours. NG2-73 was well tolerated with no serious adverse events or withdrawals due to adverse events.
In this study, NG2-73 was shown to be a novel, potent, well tolerated, effective sedative hypnotic, with dose-dependent sedation lasting between 1.5 and 6 hours. There was consistency of effect across all PD measures.
Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, obesity, pain, Parkinson's disease, restless legs syndrome (RLS), and depression. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise.
Neurogen Safe Harbor Statement
The information in this press release contains certain
forward-looking statements, made pursuant to applicable securities
laws, which involve risks and uncertainties as detailed from time
to time in Neurogen's SEC filings, including its most recent 10-K.
Such forward-looking statements relate to activities, events or
developments that Neurogen believes, expects or anti